<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262379</url>
  </required_header>
  <id_info>
    <org_study_id>CP 2005-01</org_study_id>
    <nct_id>NCT00262379</nct_id>
  </id_info>
  <brief_title>Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C</brief_title>
  <official_title>Multicenter Study, Randomized and Pragmatic, Comparing Two Therapeutic Strategies : Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C and Treated by Combination Therapy Peginterferon Alfa-2a Plus Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to demonstrate a correction of anemia in hepatitis C virus treatment with
      peginterferon plus ribavirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Show that the correction of anemia by epoetin beta (NeoRecormon®) able to maintain a optimal
      dose of ribavirin (Copegus®). The study compares two therapeutic strategies : use or non-use
      of epoetin beta (NeoRecormon®) in patients infected by chronic hepatitis C and treated by
      combination therapy Peginterferon alfa-2a (Pegasys®) plus ribavirin (Copegus®). The main
      judgement criteria are :

        -  Sustained Viral Response (Week 72)

        -  Viral Response at the End of Treatment (Week 48)

        -  Quality of life

        -  Cumulative dose of ribavirin from D0-W24 and from W24-W48 periods

        -  Clinical and biological tolerance
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response (Week 72)</measure>
    <time_frame>Week 72</time_frame>
    <description>Actual Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values up to Week 24 in the Post-treatment Follow-up Period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Viral Response at the End of Treatment (Week 48)</measure>
    <time_frame>Week 48</time_frame>
    <description>Actual Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values up to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Quality of life</measure>
    <time_frame>D0, W4, W12, W24, W48, W72</time_frame>
    <description>Questionnaire HQLQ
Fatigue Severity Scale HQLQ questionnaire and Fatigue Severity Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Cumulative dose of ribavirin from D0-W24 and from W24-W48 periods</measure>
    <time_frame>D0, W4, W8, W12, W16, W20, W24, W28, W32, W36, W40, W44, W48</time_frame>
    <description>• Cumulating dose of ribavirin during following periods D0-W24 and W24-W48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Clinical and biological tolerance</measure>
    <time_frame>D0, W4, W8, W12, W16, W20, W24, W28, W32, W36, W40, W44, W48, W52, W60, W72</time_frame>
    <description>Up to 72 weeks, includes all serious and other adverse events that newly occurred or worsened after treatment with PegIFNα-2a, ribavirin or epoetin beta</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HCV treatment with peginterferon plus ribavirin during 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Groupb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin beta (NeoRecormon®)</intervention_name>
    <description>• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female</description>
    <arm_group_label>Groupb</arm_group_label>
    <other_name>NeoRecormon®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years old or above

          -  Patient with French social security or other equivalent health assurance

          -  Patient with informed consent

          -  Serologic evidence of chronic hepatitis C by detectable anti-HCV antibodies

          -  Patient infected by HCV genotype 1, 4, 5 or 6

          -  Compensated liver disease (Child-Pugh ≤ 6)

          -  Negative urine or blood pregnancy test (for women of childbearing potential)
             documented within the 24-hour period prior the enrollment in the study

          -  All fertile males and females receiving ribavirin must have effective contraception
             during treatment and during the 6 following months

          -  Patient naive of treatment with installation of treatment by investigator following
             criteria for use Peginterferon alfa-2a (Pegasys) and ribavirin (Copegus)

        Exclusion Criteria:

          -  Women with ongoing pregnancy or breast feeding

          -  Male partner of pregnancy woman

          -  Minor

          -  Major protected by French law for biomedical study

          -  Co-infection by HBV or HIV

          -  History or other evidence of decompensated liver disease or Child-Pugh score &gt; 6

          -  Clinical or radiological evidence (abdominal ultrasound, CT scan or MRI) of
             hepatocellular carcinoma

          -  IFN or ribavirin at any previous time

          -  Patient who received an erythropoetin within 2 months before inclusion

          -  History of epilepsy (during the last 6 months)

          -  Chronic cardiac insufficiency (stage III or IV in classification from the New York
             Heart Association [NYHA])

          -  Not controlled portal hypertension

          -  Antecedents or risk of venous thrombosis

          -  Surgery within 3 months before inclusion

          -  Serum creatinine level &gt;15 mg/mL (130µmol/L)

          -  Deficiency in vitamin B9 and/or B12 (suspected with macrocytosis &gt; 105 µm3)

          -  Thrombocytosis (platelets &gt; 500 000/mm3)

          -  Chronic inflammatory syndrome (CRP &gt; 10 mg/L)

          -  Deficiency not corrected in iron :

          -  Ferritin blood level &lt; 10 µg/L Or - Transferrin saturation coefficient &lt; 20 %

          -  History of neoplasia (except basocellular epithelioma and cervical cancer)

          -  Contraindications to use epoetin beta or an excipient from molecule to study (urea,
             polysorbate 20, glycine, leucine, isoleucine, threonine, glutamic acid, phenylalanine,
             benzoic acid, benzyl alcohol)

          -  Absence of written informed consent

          -  Exclusion time for another biomedical study

          -  Patient with blood concentration of hemoglobin lower or equal to 12 g/dL for male or
             lower or equal to 11 g/dL for female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Françoise Lunel-Fabiani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Angers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84 902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Bourgoin-Jallieu</name>
      <address>
        <city>Bourgoin-Jallieu</city>
        <zip>38 317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Brest</name>
      <address>
        <city>Brest</city>
        <zip>29 609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Caen</name>
      <address>
        <city>Caen</city>
        <zip>14 033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Châteauroux</name>
      <address>
        <city>Châteauroux</city>
        <zip>36 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Corbeil-Essonnes</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91 106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Creil</name>
      <address>
        <city>Creil</city>
        <zip>60 100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21 079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Dreux</name>
      <address>
        <city>Dreux</city>
        <zip>28100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Freyming-Merlebach</name>
      <address>
        <city>Freyming-Merlebach</city>
        <zip>57 804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Grasse</name>
      <address>
        <city>Grasse</city>
        <zip>06 130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38 043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69 288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Saint-Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13 285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82 013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34 295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H montélimar</name>
      <address>
        <city>Montélimar</city>
        <zip>26 200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44 800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75 020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75 571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Pau</name>
      <address>
        <city>Pau</city>
        <zip>64 011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86 020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35 043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76 031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnault Tzanck Institute</name>
      <address>
        <city>Saint Laurent du Var</city>
        <zip>06721</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Saint-Dizier</name>
      <address>
        <city>Saint-Dizier</city>
        <zip>52 115</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31 059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59 208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Tours</name>
      <address>
        <city>Tours</city>
        <zip>37 170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>peginterferon</keyword>
  <keyword>ribavirin</keyword>
  <keyword>epoetin beta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

